Retatrutide, a experimental dual activator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising outcomes in early patient studies. Ongoing https://top10bookmark.com/story21221443/retatrutide-emerging-investigations-and-possible-medical-applications